RIGL
Rigel Pharmaceuticals, Inc.
Price Chart
Latest Quote
$32.91
-0.46 (-1.38%)
Current Price
| Previous Close | $33.37 |
| Open | $33.99 |
| Day High | $34.15 |
| Day Low | $32.43 |
| Volume | 616,077 |
Stock Information
| Shares Outstanding | 18.50M |
| Total Debt | $45.72M |
| Cash Equivalents | $146.68M |
| Revenue | $299.77M |
| Net Income | $364.23M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $608.90M |
| P/E Ratio | 1.70 |
| EPS (TTM) | $19.31 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $507.94M |
| Sales | $299.77M |
| Income | $364.23M |
| Book/sh | $21.64 |
| Cash/sh | $7.93 |
| Employees | 172 |
Financial Ratios
| Quick Ratio | 2.20 |
| Current Ratio | 2.62 |
| Debt/Eq | 11.43 |
| EPS Growth TTM | -24.40% |
Returns & Margins
| ROA | 22.88% |
| ROE | 174.08% |
| Gross Margin | 81.20% |
| Operating Margin | 20.21% |
| Profit Margin | 121.50% |
Ownership
| Insider Ownership | 3.26% |
| Institutional Ownership | 94.86% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 7.18 |
| P/S | 2.03 |
| P/B | 1.52 |
Analyst Data
| Recommendation | buy |
| Target Price | $54.20 |
Technical Indicators
| SMA20 | $30.83 |
| SMA50 | $30.19 |
| SMA200 | $34.06 |
| RSI | 66.67 |
| ATR | 1.4321 |
| Shares Float | 15.93M |
| Short Float | 21.84% |
| Short Ratio | 8.98 |
| Volatility | 1.18 |
| Rel Volume | 2.83 |
Performance History
| Week | +2.59% |
| Month | +16.29% |
| Quarter | +26.09% |
| 6 Months | -21.68% |
| YTD | -21.32% |
| Year | +71.76% |
| 3 Years | +105.69% |
| 5 Years | -18.13% |
| 10 Years | +33.78% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $32.91 | 972,700 |
| 2026-06-17 | $33.37 | 264,200 |
| 2026-06-16 | $32.46 | 388,600 |
| 2026-06-15 | $33.42 | 278,400 |
| 2026-06-12 | $32.85 | 241,500 |
| 2026-06-11 | $32.08 | 356,400 |
| 2026-06-10 | $30.91 | 210,000 |
| 2026-06-09 | $30.72 | 238,800 |
| 2026-06-08 | $30.08 | 187,400 |
| 2026-06-05 | $29.93 | 498,300 |
| 2026-06-04 | $30.25 | 230,400 |
| 2026-06-03 | $30.30 | 422,900 |
| 2026-06-02 | $30.02 | 405,700 |
| 2026-06-01 | $29.86 | 363,900 |
| 2026-05-29 | $30.49 | 350,100 |
| 2026-05-28 | $30.05 | 299,200 |
| 2026-05-27 | $29.48 | 337,000 |
| 2026-05-26 | $29.17 | 441,600 |
| 2026-05-22 | $29.01 | 183,400 |
| 2026-05-21 | $29.19 | 214,900 |
| 2026-05-20 | $28.82 | 308,800 |
| 2026-05-19 | $28.30 | 386,600 |
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
đ° Latest News
Knight Therapeutics Launches Tavalisse in Mexico
MT Newswires âĸ 2026-05-28T11:42:10ZPfizer Oncology Partnerships Add Detail To Valuation And Earnings Concerns
Simply Wall St. âĸ 2026-05-24T02:08:27Z
Pfizerâs VEPPANU License With Rigel Adds New Angle To PFE Story
Simply Wall St. âĸ 2026-05-21T05:12:31Z
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer
Benzinga âĸ 2026-05-15T20:31:07Z
Rigel Pharmaceuticals (RIGL) Is Up 20.5% After Global VEPPANU Rights Deal With Pfizer, Arvinas - Has The Bull Case Changed?
Simply Wall St. âĸ 2026-05-14T06:13:26Z
These Analysts Increase Their Forecasts On Arvinas After Q1 Results
Benzinga âĸ 2026-05-13T17:54:35Z
Pfizer Shifts VEPPANU Rights To Rigel As Valuation Gap Persists
Simply Wall St. âĸ 2026-05-13T08:17:32Z
Arvinas Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-12T14:08:57Z
We Believe Rigel Pharmaceuticals' (NASDAQ:RIGL) Earnings Are A Poor Guide For Its Profitability
Simply Wall St. âĸ 2026-05-12T12:58:02Z
Arvinas, Pfizer find new partner for âProtacâ breast cancer drug
BioPharma Dive âĸ 2026-05-12T12:05:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $19,621,000 | $18,647,000 | $7,110,000 | $1,749,000 |
| Cost Of Revenue | $19,621,000 | $18,647,000 | $7,110,000 | $1,749,000 |
| Total Revenue | $294,282,000 | $179,278,000 | $116,882,000 | $120,242,000 |
| Operating Revenue | $372,260,000 | $244,300,000 | $159,646,000 | $152,047,000 |
| Expenses | ||||
| Interest Expense | $7,320,000 | $7,918,000 | $6,872,000 | $3,707,000 |
| Total Expenses | $168,816,000 | $155,086,000 | $137,373,000 | $174,472,000 |
| Net Non Operating Interest Income Expense | $-3,639,000 | $-5,826,000 | $-4,600,000 | $-3,023,000 |
| Interest Expense Non Operating | $7,320,000 | $7,918,000 | $6,872,000 | $3,707,000 |
| Operating Expense | $149,195,000 | $136,439,000 | $130,263,000 | $172,723,000 |
| Other Income Expense | - | - | - | $-1,320,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $367,024,000 | $17,485,000 | $-25,091,000 | $-58,573,000 |
| Net Interest Income | $-3,639,000 | $-5,826,000 | $-4,600,000 | $-3,023,000 |
| Interest Income | $3,681,000 | $2,092,000 | $2,272,000 | $684,000 |
| Normalized Income | $367,024,000 | $17,485,000 | $-25,091,000 | $-57,254,320 |
| Net Income From Continuing And Discontinued Operation | $367,024,000 | $17,485,000 | $-25,091,000 | $-58,573,000 |
| Total Operating Income As Reported | $125,466,000 | $24,192,000 | $-20,491,000 | $-55,550,000 |
| Net Income Common Stockholders | $367,024,000 | $17,485,000 | $-25,091,000 | $-58,573,000 |
| Net Income | $367,024,000 | $17,485,000 | $-25,091,000 | $-58,573,000 |
| Net Income Including Noncontrolling Interests | $367,024,000 | $17,485,000 | $-25,091,000 | $-58,573,000 |
| Net Income Continuous Operations | $367,024,000 | $17,485,000 | $-25,091,000 | $-58,573,000 |
| Pretax Income | $121,827,000 | $18,366,000 | $-25,091,000 | $-58,573,000 |
| Interest Income Non Operating | $3,681,000 | $2,092,000 | $2,272,000 | $684,000 |
| Operating Income | $125,466,000 | $24,192,000 | $-20,491,000 | $-54,230,000 |
| Gross Profit | $274,661,000 | $160,631,000 | $109,772,000 | $118,493,000 |
| Special Income Charges | - | $0 | $0 | $-1,320,000 |
| Per Share | ||||
| Diluted EPS | $19.48 | $0.99 | $-1.44 | $-3.40 |
| Basic EPS | $20.40 | $0.99 | $-1.44 | $-3.40 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $-1,320 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $131,562,000 | $28,512,000 | $-16,981,000 | $-52,548,000 |
| Reconciled Depreciation | $2,415,000 | $2,228,000 | $1,238,000 | $998,000 |
| EBITDA (Bullshit earnings) | $131,562,000 | $28,512,000 | $-16,981,000 | $-53,868,000 |
| EBIT | $129,147,000 | $26,284,000 | $-18,219,000 | $-54,866,000 |
| Diluted Average Shares | $18,840,000 | $17,687,000 | $17,401,000 | $17,240,600 |
| Basic Average Shares | $17,987,000 | $17,579,000 | $17,401,000 | $17,240,600 |
| Diluted NI Availto Com Stockholders | $367,024,000 | $17,485,000 | $-25,091,000 | $-58,573,000 |
| Tax Provision | $-245,197,000 | $881,000 | $0 | $0 |
| Research And Development | $33,295,000 | $23,380,000 | $24,522,000 | $60,272,000 |
| Selling General And Administration | $115,900,000 | $113,059,000 | $105,741,000 | $112,451,000 |
| Total Unusual Items | - | $0 | $0 | $-1,320,000 |
| Total Unusual Items Excluding Goodwill | - | $0 | $0 | $-1,320,000 |
| Restructuring And Mergern Acquisition | - | $0 | $0 | $1,320,000 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $366,732,000 | $-23,812,000 | $-42,522,000 | $-28,565,000 |
| Total Assets | $513,594,000 | $163,976,000 | $117,225,000 | $134,279,000 |
| Total Non Current Assets | $273,428,000 | $28,873,000 | $17,959,000 | $18,376,000 |
| Other Non Current Assets | $1,908,000 | $1,527,000 | $3,055,000 | $640,000 |
| Non Current Deferred Assets | $245,852,000 | $0 | - | - |
| Non Current Deferred Taxes Assets | $245,852,000 | $0 | - | - |
| Goodwill And Other Intangible Assets | $24,748,000 | $27,100,000 | $13,878,000 | $14,949,000 |
| Current Assets | $240,166,000 | $135,103,000 | $99,266,000 | $115,903,000 |
| Other Current Assets | $5,207,000 | $4,523,000 | $6,261,000 | $8,259,000 |
| Prepaid Assets | $16,735,000 | $5,642,000 | - | - |
| Inventory | $11,506,000 | $6,002,000 | $5,522,000 | $9,118,000 |
| Receivables | $51,763,000 | $41,615,000 | $30,550,000 | $40,320,000 |
| Accounts Receivable | $51,763,000 | $41,615,000 | $30,550,000 | $40,320,000 |
| Allowance For Doubtful Accounts Receivable | $-338,000 | $-246,000 | $-180,000 | - |
| Gross Accounts Receivable | $52,101,000 | $41,861,000 | $30,730,000 | - |
| Cash Cash Equivalents And Short Term Investments | $154,955,000 | $77,321,000 | $56,933,000 | $58,206,000 |
| Cash And Cash Equivalents | $40,580,000 | $56,746,000 | $32,786,000 | $24,459,000 |
| Debt | ||||
| Net Debt | $11,714,000 | $2,934,000 | $26,816,000 | $14,989,000 |
| Total Debt | $53,303,000 | $59,965,000 | $60,579,000 | $41,553,000 |
| Long Term Debt And Capital Lease Obligation | $22,877,000 | $52,408,000 | $52,658,000 | $40,420,000 |
| Long Term Debt | $22,482,000 | $52,408,000 | $52,373,000 | $39,448,000 |
| Current Debt And Capital Lease Obligation | $30,426,000 | $7,557,000 | $7,921,000 | $1,133,000 |
| Current Debt | $29,812,000 | $7,272,000 | $7,229,000 | - |
| Other Current Borrowings | $29,812,000 | $7,272,000 | $7,229,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $122,114,000 | $160,688,000 | $145,869,000 | $147,895,000 |
| Total Non Current Liabilities Net Minority Interest | $22,877,000 | $97,389,000 | $92,602,000 | $82,684,000 |
| Current Liabilities | $99,237,000 | $63,299,000 | $53,267,000 | $65,211,000 |
| Other Current Liabilities | $5,000,000 | - | $3,642,000 | $4,997,000 |
| Current Deferred Liabilities | $29,071,000 | $27,795,000 | $17,039,000 | $13,514,000 |
| Payables And Accrued Expenses | $22,826,000 | $17,808,000 | $15,989,000 | $36,701,000 |
| Payables | $7,191,000 | $3,339,000 | $7,142,000 | $22,508,000 |
| Accounts Payable | $7,191,000 | $3,339,000 | $7,142,000 | $22,508,000 |
| Other Non Current Liabilities | - | $44,981,000 | $39,944,000 | $42,264,000 |
| Equity | ||||
| Common Stock Equity | $391,480,000 | $3,288,000 | $-28,644,000 | $-13,616,000 |
| Total Equity Gross Minority Interest | $391,480,000 | $3,288,000 | $-28,644,000 | $-13,616,000 |
| Stockholders Equity | $391,480,000 | $3,288,000 | $-28,644,000 | $-13,616,000 |
| Gains Losses Not Affecting Retained Earnings | $181,000 | $10,000 | $8,000 | $-153,000 |
| Other Equity Adjustments | $181,000 | $10,000 | $8,000 | $-153,000 |
| Retained Earnings | $-1,023,041,000 | $-1,390,065,000 | $-1,407,550,000 | $-1,382,459,000 |
| Other | ||||
| Ordinary Shares Number | $18,310,934 | $17,710,216 | $17,482,561 | $17,339,864 |
| Share Issued | $18,310,934 | $17,710,216 | $17,482,561 | $17,339,864 |
| Tangible Book Value | $366,732,000 | $-23,812,000 | $-42,522,000 | $-28,565,000 |
| Invested Capital | $443,774,000 | $62,968,000 | $30,958,000 | $25,832,000 |
| Working Capital | $140,929,000 | $71,804,000 | $45,999,000 | $50,692,000 |
| Capital Lease Obligations | $1,009,000 | $285,000 | $977,000 | $2,105,000 |
| Total Capitalization | $413,962,000 | $55,696,000 | $23,729,000 | $25,832,000 |
| Additional Paid In Capital | $1,414,322,000 | $1,393,325,000 | $1,378,881,000 | $1,368,822,000 |
| Capital Stock | $18,000 | $18,000 | $17,000 | $174,000 |
| Common Stock | $18,000 | $18,000 | $17,000 | $174,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $395,000 | $0 | $285,000 | $972,000 |
| Current Deferred Revenue | $29,071,000 | $27,795,000 | $17,039,000 | $13,514,000 |
| Current Capital Lease Obligation | $614,000 | $285,000 | $692,000 | $1,133,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $11,914,000 | $10,139,000 | $8,676,000 | $8,866,000 |
| Current Accrued Expenses | $15,635,000 | $14,469,000 | $8,847,000 | $14,193,000 |
| Net PPE | $920,000 | $246,000 | $1,026,000 | $2,787,000 |
| Gross PPE | $920,000 | $246,000 | $2,730,000 | $13,594,000 |
| Other Properties | $920,000 | $246,000 | $2,367,000 | $9,439,000 |
| Other Short Term Investments | $114,375,000 | $20,575,000 | $24,147,000 | $33,747,000 |
| Accumulated Depreciation | - | $-261,000 | $-1,704,000 | $-10,807,000 |
| Machinery Furniture Equipment | - | $153,000 | $363,000 | $2,048,000 |
| Leases | - | - | $0 | $2,107,000 |
| Properties | - | - | $0 | $0 |
| Construction In Progress | - | - | - | $74,000 |
| Finished Goods | - | - | - | $1,904,000 |
| Work In Process | - | - | - | $2,659,000 |
| Raw Materials | - | - | - | $4,555,000 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $75,655,000 | $31,075,000 | $-20,743,000 | $-74,208,000 |
| Operating Activities | ||||
| Operating Cash Flow | $75,655,000 | $31,471,000 | $-5,743,000 | $-73,758,000 |
| Cash Flow From Continuing Operating Activities | $75,655,000 | $31,471,000 | $-5,743,000 | $-73,758,000 |
| Operating Gains Losses | - | $-79,000 | $266,000 | $-138,000 |
| Investing Activities | ||||
| Investing Cash Flow | $-92,365,000 | $4,130,000 | $-4,297,000 | $72,777,000 |
| Cash Flow From Continuing Investing Activities | $-92,365,000 | $4,130,000 | $-4,297,000 | $72,777,000 |
| Capital Expenditure Reported | $0 | $-36,000 | $0 | $-450,000 |
| Capital Expenditure | - | $-396,000 | $-15,000,000 | $-450,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-10,000,000 | $0 | $0 |
| Financing Cash Flow | $601,000 | $-11,641,000 | $18,367,000 | $6,550,000 |
| Cash Flow From Continuing Financing Activities | $601,000 | $-11,641,000 | $18,367,000 | $6,550,000 |
| Net Common Stock Issuance | $0 | $-10,000,000 | $0 | $0 |
| Net Other Financing Charges | - | $-3,605,000 | $-2,632,000 | $-15,116,000 |
| Other | ||||
| Repayment Of Debt | $-7,500,000 | $0 | $0 | - |
| Issuance Of Debt | $0 | $0 | $19,950,000 | $19,542,000 |
| Interest Paid Supplemental Data | $6,573,000 | $7,039,000 | $5,848,000 | $2,495,000 |
| Income Tax Paid Supplemental Data | $1,063,000 | $331,000 | $81,000 | $0 |
| End Cash Position | $40,637,000 | $56,746,000 | $32,786,000 | $24,459,000 |
| Beginning Cash Position | $56,746,000 | $32,786,000 | $24,459,000 | $18,890,000 |
| Changes In Cash | $-16,109,000 | $23,960,000 | $8,327,000 | $5,569,000 |
| Proceeds From Stock Option Exercised | $8,101,000 | $1,964,000 | $1,049,000 | $2,124,000 |
| Common Stock Payments | $0 | $-10,000,000 | $0 | $0 |
| Net Issuance Payments Of Debt | $-7,500,000 | $0 | $19,950,000 | $19,542,000 |
| Net Long Term Debt Issuance | $-7,500,000 | $0 | $19,950,000 | $19,542,000 |
| Long Term Debt Payments | $-7,500,000 | $0 | $0 | - |
| Long Term Debt Issuance | $0 | $0 | $19,950,000 | $19,542,000 |
| Net Investment Purchase And Sale | $-92,365,000 | $4,428,000 | $10,444,000 | $72,334,000 |
| Sale Of Investment | $61,129,000 | $39,700,000 | $41,650,000 | $101,228,000 |
| Purchase Of Investment | $-153,494,000 | $-35,272,000 | $-31,206,000 | $-28,894,000 |
| Net Intangibles Purchase And Sale | $0 | $-360,000 | $-15,000,000 | $0 |
| Purchase Of Intangibles | $0 | $-360,000 | $-15,000,000 | $0 |
| Net PPE Purchase And Sale | $0 | $98,000 | $259,000 | $893,000 |
| Sale Of PPE | $0 | $98,000 | $259,000 | $893,000 |
| Change In Working Capital | $-19,512,000 | $153,000 | $9,517,000 | $-29,049,000 |
| Change In Other Working Capital | $3,051,000 | $12,219,000 | $3,349,000 | $1,179,000 |
| Change In Other Current Liabilities | $439,000 | $4,303,000 | $-3,336,000 | $-13,084,000 |
| Change In Other Current Assets | $-674,000 | $615,000 | $1,069,000 | $7,773,000 |
| Change In Payables And Accrued Expense | $5,303,000 | $-3,243,000 | $-4,561,000 | $2,821,000 |
| Change In Accrued Expense | $1,451,000 | $560,000 | $-4,195,000 | $-967,000 |
| Change In Payable | $3,852,000 | $-3,803,000 | $-366,000 | $3,788,000 |
| Change In Account Payable | $3,852,000 | $-3,803,000 | $-366,000 | $3,788,000 |
| Change In Prepaid Assets | $-11,848,000 | $-3,440,000 | $2,054,000 | $-513,000 |
| Change In Inventory | $-5,635,000 | $764,000 | $1,172,000 | $-2,377,000 |
| Change In Receivables | $-10,148,000 | $-11,065,000 | $9,770,000 | $-24,848,000 |
| Changes In Account Receivables | $-10,148,000 | $-11,065,000 | $9,770,000 | $-24,848,000 |
| Other Non Cash Items | $-39,981,000 | - | - | $682,000 |
| Stock Based Compensation | $12,711,000 | $12,393,000 | $8,806,000 | $12,385,000 |
| Amortization Of Securities | $-1,150,000 | $-709,000 | $-479,000 | $-63,000 |
| Deferred Tax | $-245,852,000 | $0 | $0 | - |
| Deferred Income Tax | $-245,852,000 | $0 | $0 | - |
| Depreciation Amortization Depletion | $2,415,000 | $2,228,000 | $1,238,000 | $998,000 |
| Depreciation And Amortization | $2,415,000 | $2,228,000 | $1,238,000 | $998,000 |
| Gain Loss On Sale Of PPE | $0 | $-79,000 | $266,000 | $-138,000 |
| Net Income From Continuing Operations | $367,024,000 | $17,485,000 | $-25,091,000 | $-58,573,000 |
| Purchase Of PPE | - | - | $0 | $-450,000 |
Fetched: 2026-06-17